Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Horton

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Investigation|June 4, 2024
Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiationJaimy Joy, Ana Gervassi, Lennie Chen, et al.
Nature Medicine|May 2, 2002
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infectionDavid H O'Connor, Todd M Allen, Thorsten U Vogel, et al.
Plos One|August 1, 2012
Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferationJanela McClure, Erica S Lovelace, Shokrollah Elahi, et al.
Frontiers in Immunology|March 31, 2022
Response of Human Liver Tissue to Innate Immune StimuliXia Wu, Jessica B Roberto, Allison Knupp, et al.
Bioorganic & Medicinal Chemistry Letters|August 26, 2018
Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonistsDavid C McGowan, Florence Herschke, Mourad D Khamlichi, et al.
Journal of Virology|December 26, 2001
Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infectionBianca R Mothé, Helen Horton, Donald K Carter, et al.
The Journal of Infectious Diseases|September 2, 2005
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjectsPaul A Goepfert, Helen Horton, M Juliana McElrath, et al.
Journal of Virology|October 22, 2002
Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?Thorsten U Vogel, Thomas C Friedrich, David H O'Connor, et al.
Vaccine|October 20, 2006
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul A Goepfert, Georgia D Tomaras, Helen Horton, et al.
Journal of Virology|June 20, 2002
Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239Helen Horton, Thorsten U Vogel, Donald K Carter, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Investigation|June 4, 2024
Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiationJaimy Joy, Ana Gervassi, Lennie Chen, et al.
Nature Medicine|May 2, 2002
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infectionDavid H O'Connor, Todd M Allen, Thorsten U Vogel, et al.
Plos One|August 1, 2012
Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferationJanela McClure, Erica S Lovelace, Shokrollah Elahi, et al.
Frontiers in Immunology|March 31, 2022
Response of Human Liver Tissue to Innate Immune StimuliXia Wu, Jessica B Roberto, Allison Knupp, et al.
Bioorganic & Medicinal Chemistry Letters|August 26, 2018
Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonistsDavid C McGowan, Florence Herschke, Mourad D Khamlichi, et al.
Journal of Virology|December 26, 2001
Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infectionBianca R Mothé, Helen Horton, Donald K Carter, et al.
The Journal of Infectious Diseases|September 2, 2005
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjectsPaul A Goepfert, Helen Horton, M Juliana McElrath, et al.
Journal of Virology|October 22, 2002
Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?Thorsten U Vogel, Thomas C Friedrich, David H O'Connor, et al.
Vaccine|October 20, 2006
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul A Goepfert, Georgia D Tomaras, Helen Horton, et al.
Journal of Virology|June 20, 2002
Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239Helen Horton, Thorsten U Vogel, Donald K Carter, et al.
Pageof 6